All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Abbvie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View multiple myeloma content recommended for you
Visual abstract | SUCCESSOR-2: A phase III trial of MeziKd for RRMM
Do you know... In the phase III SUCCESSOR-2 trial, by approximately how much did MeziKd reduce the risk of disease progression or death vs Kd alone?
Patients with relapsed/refractory multiple myeloma (RRMM) who have been exposed or are refractory to lenalidomide and an anti-CD38 monoclonal antibody represent a growing population with limited validated treatment options. Mezigdomide, an oral cereblon E3 ligase modulator (CELMoD), is under investigation in combination with carfilzomib + dexamethasone (MeziKd) for the treatment of patients with RRMM whose disease has progressed after ≥1 prior line of therapy.
SUCCESSOR-2 (NCT05552976) is a randomized, phase III trial evaluating MeziKd vs Kd alone in this patient population. The primary endpoint is progression-free survival (PFS), with overall survival as a key secondary endpoint.
Here, we present a visual abstract summarizing key efficacy and safety findings from the phase III SUCCESSOR-2 trial.
This educational resource is independently supported by BMS. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?
